Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor

A composition, comprising:

• a therapeutically acceptable combination of a UCP and/or Fas antibody or other inhibitor, or combination thereof., and a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor.

The composition of claim 57 further comprising one or more chemotherpeutic agents.

A kit, comprising:

• a container housing a therapeutically acceptable amount of a first pharmacon comprising a UCP and/or Fas antibody or other inhibitor, and a container housing a therapeutically acceptable amount of a second pharmacon selected from a fatty acid metabolism inhibitor and a glucose metabolism inhibitor.

A method, comprising:

• administering a fatty acid metabolism inhibitor, or a pharmaceutically acceptable salt thereof, to a cell whereby to increase the amount of UCP on the surface of the cell;
• and
• exposing the cell to an inhibitor selected from the group consisting of a UCP inhibitor and a Fas inhibitor.

A method, comprising:

• administering, to a wound in a subject, a therapeutically acceptable amount of a composition comprising an agent able to alter production of reactive oxygen in cells located within or proximate the wound.

An article, comprising:

• a substrate comprising cells exposed to an agent able to alter production of reactive oxygen in a cell.

A method, comprising:

• increasing the amount of UCP on the surface of a cell;
• and
• exposing the cell to at least one of a UCP inhibitor or a Fas inhibitor.